Health Canada Proposes Ministerial Reliance Order to Accelerate Drug Approvals Through Foreign Regulatory Collaboration
核心洞察
Health Canada announced consultations on December 19, 2025, for a proposed Ministerial Reliance Order (搜索) that would allow reliance on foreign regulatory authority decisions to expedite drug reviews and encourage earlier market availability in Canada.
The proposed order establishes three deeming categories including authorized foreign drugs, submissions filed within 120 days of foreign applications, and joint reviews with trusted international regulators.
Manufacturers must demonstrate drug equivalence in strength, dosage form, route of administration, and medicinal ingredients while ensuring conditions of use fall within foreign drug parameters.
Health Canada announced on December 19, 2025, the launch of consultations on a proposed Ministerial Reliance Order (搜索) designed to accelerate drug availability in the Canadian market by allowing the regulatory agency to rely on decisions and documents from foreign trusted regulators. The initiative represents a key component of Health Canada's Red Tape Review report aimed at modernizing drug approval processes.
Regulatory Framework and Authority
The proposed Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs operates under Section 30.06(1) of the Food and Drugs Act (搜索). This provision grants the Minister authority to "deem that specified requirements of this Act or the regulations are met — in respect of a therapeutic product or food that belongs to a class specified in the order — on the basis of a decision of, or any information or document produced by, a foreign regulatory authority."
The Minister may only issue such orders when believing on reasonable grounds that the action is necessary for health or safety purposes or serves the public interest, and that it is unlikely to result in unacceptable health, safety, or environmental risks.
Three-Category Deeming Structure
The proposed Reliance Order establishes three distinct deeming categories for different submission types:
Category 1: Authorized Foreign Drugs applies to new drug submissions (搜索) (NDSs), abbreviated new drug submissions (搜索) (ANDSs), and their supplements where a foreign drug is already authorized by a trusted foreign regulatory authority.
Category 2: Early Filing Submissions covers non-comparative NDSs and supplement NDSs filed within 120 days of a foreign application submission. This category enables manufacturers to leverage anticipated positive foreign regulatory decisions by filing early with Health Canada.
Category 3: Joint Reviews applies exclusively to NDSs where Health Canada conducts collaborative reviews with one or more foreign regulatory authorities listed in the incorporated by reference list.
Implementation Requirements
For all categories, manufacturers must indicate their intent to have Section C.08.004 requirements deemed met regarding non-clinical, clinical, and chemistry and manufacturing information. The proposed order requires manufacturers to demonstrate that their drug belongs to a specified class on the incorporated by reference list and has been authorized by a listed foreign regulatory authority.
Critical equivalency requirements include identical strength, dosage form, route of administration, and medicinal ingredient composition compared to the foreign-authorized drug. Additionally, the conditions of use for the Canadian submission must fall within the parameters established for the foreign drug, and any differences must not negatively impact safety or effectiveness.
Foreign Regulatory Authority Selection
The Regulatory Impact Analysis Statement indicates that decisions to add foreign regulatory authorities to the incorporated by reference list will consider multiple factors including similarity to Canadian requirements and standards, history of collaboration with Health Canada, and demonstrated track record of conducting thorough reviews consistent with Health Canada's standards.
The proposed framework specifically mentions that classes of drugs including pediatric conditions (搜索) of use not currently authorized in Canada could be added to the list, potentially expanding treatment options for underserved patient populations.
Post-Market and Intellectual Property Considerations
The proposed order maintains robust post-market oversight requirements, mandating that manufacturers notify Health Canada as post-market measures related to foreign drug authorization are fulfilled, including any confirmatory trials required by foreign jurisdictions.
Existing intellectual property protections remain intact under the proposed framework. Data protection, protection under the Patented Medicines (Notice of Compliance) Regulations, and Certificate of Supplementary Protection regime benefits continue to apply regardless of the reliance order's implementation. These protections extend to comparative submissions including generic drug ANDSs and biosimilar drug NDSs.
Consultation Timeline
Health Canada has opened the consultation period for stakeholder input on the proposed Ministerial Reliance Order (搜索), with comments accepted until February 28, 2026. The agency has also issued additional stakeholder information to complement the draft order and provide guidance on interpreting the proposed requirements.
The initiative represents a significant step toward regulatory harmonization and could substantially reduce drug approval timelines while maintaining safety standards through reliance on established international regulatory partnerships.